secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2023-05-03T23:59:59+00:00
Accession:  0001558370-23-007746
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GlycoMimetics Q1 cash $65M; uproleselan Phase 3 trial on track for H1 2024 survival trigger
--------------------------------------------------------------------------------

- Cash and equivalents $65.0M as of March 31, 2023, up from $47.9M at Dec 31, 2022; raised $28.7M via ATM.
- R&D expenses fell to $5.4M from $9.6M YoY on lower clinical trial costs after Phase 3 enrollment completed.
- Phase 3 uproleselan study continues; final overall survival event trigger projected within first half of 2024.
- Cash runway expected to fund operations into late Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000155837023007746/0001558370-23-007746-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000155837023007746/glyc-20230503x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-007746

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer